SUPPLEMENT TO:
Financial Support Provided by
Management of Type 2 Diabetes in People With Renal Impairment
Diabetes is a progressive disease associated with micro- and macrovascular complications. Type 2 diabetes (T2D) is the leading contributor to chronic kidney disease (CKD) worldwide, which itself is associated with an increased burden of cardiovascular disease, increased risk of hypoglycemia, and increased risk of death beyond that caused by diabetes alone. In a series of short videos now available on The Journal of Family Practice website, the authors discuss how CKD in people with T2D is defined, potential consequences of CKD in this patient population, and how those with CKD and T2D should be identified, monitored, and treated.
This peer-reviewed publication was developed in adherence with Good Publication Practice (GPP3) guidelines. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship and have disclosed all potential conflicts of interest.
Video 1: Introduction
Video 2: Renal Disease and Type 2 Diabetes
Video 3: Identifying and Monitoring People With Type 2 Diabetes at Risk for the Development of Renal Disease
Video 4: Glycemic Management of Patients With Renal Disease and Type 2 Diabetes
Video 5: Use of Basal Insulin in People With Type 2 Diabetes and Renal Disease
Video 1: Introduction
About the Authors
Biographies
Alice YY Cheng, MD, FRCPC
Dr Cheng is an endocrinologist at Trillium Health Partners and Unity Health Toronto and is Associate Professor at the University of Toronto. She has served on the Expert Committee for the Diabetes Canada clinical practice guidelines since 2003, while also serving on the Steering Committee for the 2008 revision, and as Chair for the 2013 version. She is actively involved in continuing education and has received a Certificate of Recognition from the Ontario College of Family Physicians for her contributions to diabetes care and family medicine education. Currently, she is Chair of the Professional Section of Diabetes Canada and Associate Editor for the Canadian Journal of Diabetes. In recognition of her contribution, Dr Cheng has received the national Charles H. Best Award, and the Gerald S. Wong Service Award from Diabetes Canada. She is also the creator of The Med Ed Pledge – an initiative to increase diversity and inclusion in continuing medical education.Lance Sloan, MD, MSE, FACE, FASN, FACP
Dr Sloan is triple board certified in Endocrinology, Nephrology, and Internal Medicine, and is a Fellow of the American College of Endocrinology, the American Society of Nephrology, and the American College of Physicians. Currently, he is President of the Texas Institute for Kidney and Endocrine Disorders and is Medical Director of SNG Lufkin Dialysis. He is also Clinical Assistant Professor at the University of Texas Medical Branch in Galveston, Texas. Dr Sloan is past president of the Texas chapter of the American Association of Clinical Endocrinology (AACE) and has been a regional leader for the Renal Physicians Association (RPA) and a member of the Texas Diabetes Council Health Care Professionals Advisory Committee, and the Clinical Practice and Government Affairs Committees for the RPA.John Anderson, MD
Dr Anderson practices internal medicine and diabetes at the Frist Clinic in Nashville, Tennessee. He is Past President of the 38-member multi-specialty clinic, and has served in leadership roles at Centennial Medical Center, a 670-bed HCA tertiary care referral hospital. He has also served as Chair of the Department of Medicine for two separate terms and has been a member and Chair of the Board of Trustees of Centennial. He has received numerous honors including recognition as a "Top Doctor", Nashville Business Journal 2010–2017 and Honorary Fellow of India College of Physicians and Doctor of Humane Letters, New York College of Podiatric Medicine. Dr Anderson is Past President, Medicine & Science of the American Diabetes Association (ADA) and has served two separate terms on the National Board of Directors, as well as three years on the Executive Committee.
Dr Anderson has been an ADA volunteer for more than 25 years, both locally and nationally. He has participated on multiple committees and task forces, including Chair of the Advocacy Committee and Co-Chair of the ADA’s Health Reform Task Force. In 2013, Dr Anderson received the Banting Medal for Scientific Achievement, the highest scientific award of the ADA, for his service as President of Medicine & Science.
DISCLOSURES
Alice YY Cheng, MD, FRCPC
Consultant and Speaker: Abbott, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, HLS Therapeutics, Janssen, Medtronic, Merck, Novartis, Novo Nordisk, and Sanofi; Clinical trial involvement: Applied Therapeutics, Boehringer Ingelheim, Eli Lilly, and Sanofi.Lance Sloan, MD, MSE, FACE, FASN, FACP
Consultant and Speaker: AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Janssen; Clinical trial involvement: Boehringer Ingelheim, Eli Lilly, and Sanofi.John Anderson, MD
Consultant/Advisory Boards: Abbott, AstraZeneca, Eli Lilly, Janssen, Mannheim, Merck, Novo Nordisk, Sanofi; Speaker’s Bureau: AstraZeneca, Eli Lilly, Janssen, Novo Nordisk, and Sanofi.
ACKNOWLEDGEMENTS
- Financial support for this digital publication was provided by Sanofi US. The authors wish to thank Dr Luigi F Meneghini for his contribution to and review of the materials in this digital publication. The authors received writing and editorial support in the preparation of the videos and abstract provided by Barrie Anthony, PhD, CMPP, of Evidence Scientific Solutions, funded by Sanofi US.